QIAGEN Aktie
WKN DE: A40ZZU / ISIN: NL0015002CX3
15.01.2025 14:13:00
|
QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024.
Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by phone
U.S.: +1 646 828 8193
UK: +44 (0)330 165 4027
GER: +49 (0)69 6610 2480
Conference ID: 9237018
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast - Click here: Access Webcast
A conference call replay will be available by using the following link:
https://event.webcasts.com/starthere.jsp?ei=1684130&tp_key=c56f1d6ba2
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
Source: QIAGEN N.V.
Category: Financial
View source version on businesswire.com: https://www.businesswire.com/news/home/20250115503089/en/

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu QIAGEN N.V.mehr Nachrichten
15:59 |
XETRA-Handel TecDAX schwächelt (finanzen.at) | |
15:59 |
Zurückhaltung in Frankfurt: So entwickelt sich der LUS-DAX aktuell (finanzen.at) | |
15:59 |
Börse Frankfurt in Rot: DAX am Freitagnachmittag schwächer (finanzen.at) | |
10:04 |
DAX 40-Wert QIAGEN-Aktie: So viel Verlust wäre bei einem Investment in QIAGEN von vor einem Jahr angefallen (finanzen.at) | |
09:29 |
Anleger in Frankfurt halten sich zurück: LUS-DAX zum Start des Freitagshandels im Minus (finanzen.at) | |
09:29 |
Gute Stimmung in Frankfurt: DAX legt zum Start des Freitagshandels zu (finanzen.at) | |
09:29 |
TecDAX aktuell: TecDAX notiert zum Start im Plus (finanzen.at) | |
10.04.25 |
Aufschläge in Frankfurt: TecDAX schließt deutlich im Plus (finanzen.at) |
Analysen zu QIAGEN N.V.mehr Analysen
07.04.25 | QIAGEN Buy | Deutsche Bank AG | |
07.04.25 | QIAGEN Neutral | UBS AG | |
07.04.25 | QIAGEN Buy | Jefferies & Company Inc. | |
28.03.25 | QIAGEN Buy | Jefferies & Company Inc. | |
21.02.25 | QIAGEN Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Aktien in diesem Artikel
QIAGEN N.V. | 36,50 | 2,20% |
|